| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/10/2002 | CN1344266A Novel compounds |
| 04/10/2002 | CN1344257A Fused pydiopyridazine inhibitors of cGMP phosphodiesterase |
| 04/10/2002 | CN1344256A (Hetero) aryl-bicyclic heteroaryl derivatives, their prepn. and their use as protease inhibitors |
| 04/10/2002 | CN1344249A 酰胺衍生物 Amide derivatives |
| 04/10/2002 | CN1344247A Multicyclic compounds which inhibit beukocyte adhesion mediated by VLA-4 |
| 04/10/2002 | CN1344245A Branched chain amino acid-dependent aminotransferase inhibitors and their use in treatment of diabetic retinopathy |
| 04/10/2002 | CN1344162A Medical compsns. |
| 04/10/2002 | CN1344161A Use of pyridazino [4,5-i(b)]indole-1-acetamide derivatives for preparing medicines for treating disease related to dysfunction of peripheral benzodiazepin receptors |
| 04/10/2002 | CN1344160A Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 04/10/2002 | CN1344159A Combinations for treatment of diseases involving angiogenesis |
| 04/10/2002 | CN1344155A Transnasal transport/immunisation with highly adaptable carriers |
| 04/10/2002 | CN1343663A Amlodipine-series salts and preparing process and application thereof |
| 04/10/2002 | CN1343512A Process for preparing vasculitis medicine |
| 04/10/2002 | CN1343501A Medicine for treating early heartbeat |
| 04/09/2002 | US6369236 Imidazole derivatives with biphenylsulfonyl substitution method for preparing them and their use as a drug or diagnostic agent |
| 04/09/2002 | US6369227 Thrombin or factor Xa inhibitors |
| 04/09/2002 | US6369222 mGluR antagonists and a method for their synthesis |
| 04/09/2002 | US6369221 Anticonvulsants, antiischemic agents; brain and nervous system disorder treatment |
| 04/09/2002 | US6369210 22012, human carboxypeptidase |
| 04/09/2002 | US6369193 Contulakin-G, analogs thereof and uses therefor |
| 04/09/2002 | US6369103 Hmg coa reductase inhibitor such as pravastatin to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia |
| 04/09/2002 | US6369100 Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
| 04/09/2002 | US6369099 Method of locking 1 α-OH of vitamin D compounds in axial orientation |
| 04/09/2002 | US6369094 3-(n-methyl-2(r)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl )-1h-indole, analgesic for migrane |
| 04/09/2002 | US6369089 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| 04/09/2002 | US6369086 Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors |
| 04/09/2002 | US6369084 Prostaglandin mediated diseases |
| 04/09/2002 | US6369079 Methods for treating irritable bowel syndrome using optically pure (+) norcisapride |
| 04/09/2002 | US6369076 Analgesics |
| 04/09/2002 | US6369075 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B |
| 04/09/2002 | US6369073 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 04/09/2002 | US6369071 Treatment of angina pectoris |
| 04/09/2002 | US6369069 Cardiovascular disorders |
| 04/09/2002 | US6369065 CD40 signal blocking agent |
| 04/09/2002 | US6369064 Triazolo(4,5-d)pyrimidine compounds |
| 04/09/2002 | US6369063 Selective factor Xa inhibitors |
| 04/09/2002 | US6369062 Sustained release ranolazine formulations |
| 04/09/2002 | US6369059 Tetracyclic derivatives, process of preparation and use |
| 04/09/2002 | US6369045 Phospholipase A2 inhibitors thereof and use of same in diagnosis and therapy |
| 04/09/2002 | US6369039 Saturated solution; catheter |
| 04/09/2002 | US6369034 For therapy of cancer, restenosis, and atherosclerosis |
| 04/09/2002 | US6368797 Determining the genotype at nucleotide 192 of a gene that is an indicator of an increased risk for alzheimer's disease by performing restriction enzyme digestion of an amplified product of the nucleic acid molecule |
| 04/09/2002 | US6368640 Method and composition for improving sexual fitness |
| 04/09/2002 | CA2229000C 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| 04/09/2002 | CA2090321C Therapeutically useful 2-aminotetralin derivatives |
| 04/09/2002 | CA2071224C Quinoline derivatives, their production and use |
| 04/04/2002 | WO2002027318A1 Methods and compositions for screening modulators of lipid kinases |
| 04/04/2002 | WO2002026984A2 Potassium channel interactors and uses therefor |
| 04/04/2002 | WO2002026982A2 Secreted human proteins |
| 04/04/2002 | WO2002026977A1 Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing |
| 04/04/2002 | WO2002026947A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 04/04/2002 | WO2002026946A2 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof |
| 04/04/2002 | WO2002026929A2 Kini-3 motor protein and methods for its use |
| 04/04/2002 | WO2002026826A2 Proteins and nucleic acids encoding same |
| 04/04/2002 | WO2002026825A2 G-protein coupled receptors |
| 04/04/2002 | WO2002026782A2 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/04/2002 | WO2002026781A2 Ige receptor antagonists |
| 04/04/2002 | WO2002026774A2 Melanocortin receptor ligands |
| 04/04/2002 | WO2002026752A1 α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES |
| 04/04/2002 | WO2002026737A1 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| 04/04/2002 | WO2002026734A1 PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa |
| 04/04/2002 | WO2002026733A2 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 04/04/2002 | WO2002026729A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 04/04/2002 | WO2002026727A2 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | WO2002026724A1 Cyclized benzamide neurokinin antagonists for use in therapy |
| 04/04/2002 | WO2002026723A1 Compounds useful in the treatment of inflammatory diseases |
| 04/04/2002 | WO2002026722A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 04/04/2002 | WO2002026717A2 Hydroxy acid integrin antagonists |
| 04/04/2002 | WO2002026711A1 Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases |
| 04/04/2002 | WO2002026709A1 Process for producing multiform crystal of donepezil hydrochloride |
| 04/04/2002 | WO2002026704A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | WO2002026324A2 Tocol-based compositions containing amiodarone |
| 04/04/2002 | WO2002026256A1 Excessive antibody production inhibitors, process for producing the same and method of using the same |
| 04/04/2002 | WO2002026245A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
| 04/04/2002 | WO2002026227A1 Lactone integrin antagonists |
| 04/04/2002 | WO2002026223A2 Catecholamine pharmaceutical compositions and methods |
| 04/04/2002 | WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | WO2002026031A1 Method of constructing heart failure model animal |
| 04/04/2002 | WO2002014281A8 Pyridine derivatives as inhibitors of p38 |
| 04/04/2002 | WO2002004636A8 NOVEL α-CATENIN EXPRESSED IN HEART AND TESTIS |
| 04/04/2002 | WO2002004421A3 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 04/04/2002 | WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor |
| 04/04/2002 | WO2001094347A8 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 04/04/2002 | WO2001090079A3 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists |
| 04/04/2002 | WO2001089451A3 Protease inhibitors |
| 04/04/2002 | WO2001088532A3 Improved assay techniques using nematode worms |
| 04/04/2002 | WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/04/2002 | WO2001087263A3 Delivery systems for treatment of vascular disease |
| 04/04/2002 | WO2001085980A3 Enzymatic assays for screening anti-cancer agents |
| 04/04/2002 | WO2001085227A3 Nitric oxide-releasing metallic medical devices |
| 04/04/2002 | WO2001085100A3 Vasodilator-thrombolytic fusion proteins and conjugates |
| 04/04/2002 | WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 04/04/2002 | WO2001073033A3 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 04/04/2002 | WO2001072839A3 Human g-protein coupled receptors |
| 04/04/2002 | WO2001072829A3 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 04/04/2002 | WO2001070678A3 Substituted biphenyl derivatives |
| 04/04/2002 | WO2001066098A3 Therapeutic uses of ppar mediators |
| 04/04/2002 | WO2001062799A3 Method for inhibiting angiogenesis using molecules that enhance plasmin activity |
| 04/04/2002 | WO2001060375A3 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration |
| 04/04/2002 | WO2001060350A3 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |